View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsNeoleukin Therapeutics 将来の成長Future 基準チェック /06現在、 Neoleukin Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Sep 12Price target decreased to US$10.50Down from US$13.14, the current price target is an average from 6 analysts. New target price is 881% above last closing price of US$1.07. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • Aug 12Price target decreased to US$11.71Down from US$13.14, the current price target is an average from 6 analysts. New target price is 893% above last closing price of US$1.18. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • Jul 06Price target decreased to US$13.14Down from US$15.00, the current price target is an average from 5 analysts. New target price is 1,201% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • May 30Price target decreased to US$15.00Down from US$18.29, the current price target is an average from 6 analysts. New target price is 1,400% above last closing price of US$1.00. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • Apr 27Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 1,363% above last closing price of US$1.25. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • Mar 22Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 847% above last closing price of US$1.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.すべての更新を表示Recent updatesお知らせ • Jan 16Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNeoleukin Therapeutics, Inc. announced the appointment of Julie Jordan, M.D., as Chief Medical Officer. Dr. Jordan brings to Neurogene over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases. In her prior role as Chief Medical Officer of Homology Medicines, Dr. Jordan was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company’s pipeline of gene therapy and gene editing candidates for rare diseases. Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company’s Senior Vice President, Head of Clinical Development and Operations. During her tenure, she successfully drove development and navigated regulatory challenges for multiple first-in-class genetic medicines, built and led a team of functional experts across multiple disciplines, and played a key role in strengthening relationships with patient advocacy groups and key opinion leaders. Before joining Homology Medicines, she held global leadership roles of increasing responsibility for central nervous system, neuropsychiatry, and other programs at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Before joining industry, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School.お知らせ • Dec 20+ 1 more updateNeurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction.Neurogene Inc. entered into a term sheet to acquire Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders in a reverse merger transaction on June 2, 2023. Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $180 million in a reverse merger transaction on July 17, 2023. Subject to the terms of the merger agreement, each outstanding share of Neurogene capital stock will be converted solely into the right to receive a number of shares of Neoleukin common stock, equal to the exchange ratio, estimated to be approximately 1.7374 shares of Neoleukin common stock for each share of Neurogene’s common stock. Post merger Neoleukin stockholders are expected to own approximately 16% of the combined company and pre-merger Neurogene stockholders (including those purchasing Neurogene shares in the concurrent private financing) are expected to own approximately 84% of the combined company. Upon completion of the merger the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”. Under specified circumstances, Neoleukin may be required to pay Neurogene a termination fee of $3.04 million and Neurogene may be required to pay Neoleukin a termination fee of $12 million. The combined company will be led by Rachel McMinn, Founder and Chief Executive Officer of Neurogene, and other members of the Neurogene management team. The combined company’s Board of Directors will be comprised of five board members selected by Neurogene and two members selected by Neoleukin.The transaction is subject to approval by Neurogene and Neoleukin stockholders, the effectiveness of a registration statement, Nasdaq’s approval of the listing of the shares of Neoleukin common stock to be issued in connection with the merger, Neurogene’s receipt (or receipt simultaneous with the Closing of the merger) of cash proceeds from its private placement of not less than $75 million, Neoleukin net cash, as finally determined in accordance with the Merger Agreement, equaling an amount not less than $60 million and the satisfaction of customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both Neurogene and Neoleukin. Neoleukin’s board of directors unanimously recommends that Neoleukin stockholders vote for the merger. The merger is expected to close in the fourth quarter of 2023. TD Cowen is serving as exclusive financial advisor to Neurogene. TD Cowen and Stifel are serving as placement agents on Neurogene’s planned concurrent private financing. Ryan A. Murr and Branden C. Berns of Gibson Dunn & Crutcher LLP are serving as legal counsel and legal due diligence provider to Neurogene and Cooley LLP is serving as legal counsel to the placement agents. Leerink Partners LLC acted as the exclusive financial advisor and fairness opinion provider to Neoleukin Board. David K. Michaels and Jeremy R. Delman of Fenwick & West LLP are serving as legal counsel and legal due diligence provider to Neoleukin. Equiniti Trust Company, LLC acted as transfer agent for Neoleukin and American Stock Transfer & Trust Company, LLC acted as transfer agent for Neurogene. Morrow Sodali LLC acted as proxy solicitor to Neoleukin for a fee of $20,000, plus reimbursement of out-of-pocket expenses. In connection with Leerink Partners’ services as financial advisor to Neoleukin, Neoleukin has agreed to pay Leerink Partners an aggregate fee of $2.5 million, $500,000 of which became payable upon the rendering of its opinion and the remainder of which is payable contingent upon consummation of the merger.Neurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction on December 18, 2023. As a result of and upon the effective time of the Merger (as defined herein), among other things, (a) each then-issued and outstanding share of Class A Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class A Common Stock ”) converted automatically into 0.0756 shares of common stock, par value $0.000001 per share, of Neoleukin (the “Company Common Stock” and prior to the effective time of the Merger, the “Neoleukin Common Stock”), (b) each then-issued and outstanding share of Class B Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class B Common Stock” and, together with Neurogene Class A Common Stock, “Neurogene Common Stock”), converted automatically into 0.0756 shares of Company Common Stock, (c) each then-issued and outstanding share of Series A-1 Preferred Stock, par value $0.0001 per share, of Neurogene (“ Neurogene Series A-1 Preferred Stock ”) converted automatically into 0.0756 shares of Company Common Stock, (d) each then-issued and outstanding share of Series A-2 Preferred Stock, par value $0.0001 per share, of Neurogene (“Neurogene Series A-2 Preferred Stock”) converted automatically into 0.0756 shares of Company Common Stock, (e) each then-issued and outstanding share of Series B Preferred Stock, par value $0.0001 per share (“Neurogene Series B Preferred Stock” and together with the Neurogene Common Stock, the Neurogene Series A-1 Preferred Stock and the Neurogene Series A-2 Preferred Stock, the “Neurogene Capital Stock”) converted automatically into 0.0756 shares of Company Common Stock, and (f) each then-issued and outstanding pre-funded warrant of Neurogene, each representing a right to acquire one share of Neurogene Common Stock for $1.559999 per pre-funded warrant (each, a “Neurogene Pre-Funded Warrant”), converted automatically, on a one-for-one basis, into a pre-funded warrant of the Company (each, a “ Company Pre-Funded Warrant”) that represents a right to acquire 0.0756 shares of Company Common Stock at an exercise price of $0.000001 per share. In connection with the completion of the Merger, Neoleukin changed its name from “Neoleukin Therapeutics, Inc.” to “Neurogene Inc.” (the “Company Name Change”). As of December 19, 2023, Neurogene shares are expected to begin trading on the NASDAQ Global Market under the ticker “NGNE” beginning today at the market open. The Board has determined that Robert Baffi, Cory Freedland, Sarah Noonberg, Rohan Palekar and Robert Keith Woods (“ Keith Woods ”), each of whom is a current member of the Board, qualify as “independent directors” as defined by the Nasdaq Listing Rules. The Neoleukin board of directors previously determined that former directors Martin Babler, M. Cantey Boyd, Erin Lavelle, Todd Simpson and Rusty Williams were “independent” under the Nasdaq Listing Rules. Immediately after the effective time the Merger on December 18, 2023, the Board appointed Rachel McMinn as the Company’s Chief Executive Officer and Christine Mikail as the Company’s President and Chief Financial Officer, each to serve at the discretion of the Board. Immediately after the effective time the Merger on December 18, 2023, the Board appointed the following four individuals to the Board: Rachel McMinn, Robert Baffi, Cory Freedland and Keith Woods. Rachel McMinn was also appointed as Chair of the Board. Concurrent with the closing of the merger, Neurogene closed an oversubscribed $95 million private financing, led by new and existing healthcare-dedicated specialist and mutual fund institutional investors, including participation from Great Point Partners, EcoR1 Capital, Redmile Group, Samsara BioCapital, Janus Henderson Investors, funds and accounts managed by Blackrock, Casdin Capital, Avidity Partners, Arrowmark Partners, Cormorant Asset Management, Alexandria Venture Investments, and a healthcare investment fund. Neurogene’s cash, cash equivalents, and investments of approximately $200 million, before payment of final transaction-related expenses, are expected to fund operations and multiple potentially value-creating milestones into the second half of 2026. Neoleukin convened and adjourned the Special Meeting on December 13, 2023. At the Special Meeting, Neoleukin’s stockholders approved, among other matters, amendments to the amended and restated certificate of incorporation of Neoleukin to (i) increase the number of authorized shares of Company Common Stock from 20,000,000 shares (after giving effect to the 1-for-5 reverse stock split that was effected on September 25, 2023) to 500,000,000 (the “Authorized Share Increase”) and (ii) effect the Reverse Stock Split. Following the Special Meeting, the Neoleukin board of directors approved the Reverse Stock Split at a ratio of 1:4.お知らせ • Sep 23Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementNeoleukin Therapeutics, Inc. announced that its board of directors (‘Board’) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin’s common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin’s existing trading symbol ‘NLTX’ with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin’s plan to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. The reverse stock split was approved by Neoleukin’s stockholders at the Company’s 2023 Annual Meeting of Stockholders held on June 8, 2023, to be effected in the Board’s discretion within approved parameters.New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (US$29.5m market cap).分析記事 • Jul 18Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Mar 10Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Nov 19We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 3 experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 01Neoleukin Therapeutics Receives Notice from the Nasdaq Stock Market LLC for Minimum Bid Price RequirementOn October 26, 2022, Neoleukin Therapeutics, Inc. (the ‘Company’) received notice (the ‘Notice’) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (‘Nasdaq’) that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until April 24, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to April 24, 2023. If the Company does not regain compliance by April 24, 2023, the Company may be eligible for an additional 180 calendar day grace period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Global Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Market until the completion of the appeal process. The Company is considering actions that it may take in response to this Notice in order to regain compliance with the continued listing requirements, but no decisions about a response have been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.Price Target Changed • Sep 12Price target decreased to US$10.50Down from US$13.14, the current price target is an average from 6 analysts. New target price is 881% above last closing price of US$1.07. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.Price Target Changed • Aug 12Price target decreased to US$11.71Down from US$13.14, the current price target is an average from 6 analysts. New target price is 893% above last closing price of US$1.18. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.お知らせ • Jul 28Neoleukin Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Neoleukin Therapeutics, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 09, 2022Price Target Changed • Jul 06Price target decreased to US$13.14Down from US$15.00, the current price target is an average from 5 analysts. New target price is 1,201% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.お知らせ • Jun 26Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic IndexNeoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic Index分析記事 • Jun 03Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • May 30Price target decreased to US$15.00Down from US$18.29, the current price target is an average from 6 analysts. New target price is 1,400% above last closing price of US$1.00. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.お知らせ • May 18Neoleukin Therapeutics, Inc. Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating Nl-201 in Combination with Keytruda® (Pembrolizumab)Neoleukin Therapeutics, Inc. announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study, which is being conducted through a clinical collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.お知らせ • May 10Neoleukin Therapeutics, Inc. Provides NL-201 UpdateNeoleukin Therapeutics, Inc. provided NL-201 Update. Neoleukin is conducting a clinical trial of intravenous NL-201 in patients with advanced solid tumors. It is currently enrolling patients at sites in Australia, the United States, and Canada, evaluating two different schedules and multiple dose levels in order to determine a recommended Phase 2 dose and schedule. Neoleukin anticipates disclosing interim data during the second half of 2022. Based on encouraging preclinical activity, Neoleukin announced plans to initiate a separate clinical trial to evaluate NL-201 in patients with hematologic malignancies. The timing for enrolling patients in this trial will be determined based on data the company receive from the company's ongoing solid tumor Phase 1 trial relating to safety and optimal dosing schedules.Price Target Changed • Apr 27Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 1,363% above last closing price of US$1.25. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 01Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022, at 13:30 Pacific Standard Time. Agenda: To elect Jonathan G. Drachman and Sarah B. Noonberg as class ii directors of the company to hold office until the 2025 annual meeting of stockholders; to ratify the appointment of deloitte & touche llp as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2022; to approve, by a non-binding advisory vote, the compensation paid by the company to its named executive officers; and to conduct any other business properly brought before the meeting.Price Target Changed • Mar 22Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 847% above last closing price of US$1.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.お知らせ • Mar 03Neoleukin Therapeutics Inc. Announces Executive ChangesNeoleukin Therapeutics Inc. announced the appointment of Rohan Palekar, Chief Executive Officer of 89bio, Inc, to Neoleukin's Board of Directors, and the departure of Lewis Rusty Williams, MD, PhD, from the board. Mr. Palekar has served as the CEO of 89bio since June 2018.Price Target Changed • Mar 03Price target decreased to US$19.71Down from US$21.57, the current price target is an average from 6 analysts. New target price is 625% above last closing price of US$2.72. Stock is down 77% over the past year.お知らせ • Feb 24Neoleukin Therapeutics, Inc. to Report Fiscal Year 2021 Results on Mar 01, 2022Neoleukin Therapeutics, Inc. announced that they will report fiscal year 2021 results After-Market on Mar 01, 2022お知らせ • Feb 16+ 1 more updateNeoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.お知らせ • Jan 12Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)Neoleukin Therapeutics, Inc. announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The agreement will allow for the evaluation of safety and efficacy of Neoleukin’s NL-201, a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in an ongoing Phase 1 trial. Neoleukin will evaluate NL-201 plus pembrolizumab as part of the company’s ongoing Phase 1 trial in patients with advanced, relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study. The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity.お知らせ • Dec 12Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies At American Society of Hematology Annual MeetingNeoleukin Therapeutics, Inc. announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without a bias toward cells expressing the IL-2 receptor alpha subunit (CD25). NL-201 is currently in a Phase 1 clinical trial for patients with solid tumors.Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Neoleukin Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:NLTX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/2023N/A-34-33-32N/A6/30/2023N/A-43-38-37N/A3/31/2023N/A-56-46-45N/A12/31/2022N/A-58-47-46N/A9/30/2022N/A-59-48-47N/A6/30/2022N/A-62-48-46N/A3/31/2022N/A-61-51-48N/A12/31/2021N/A-61-51-48N/A9/30/2021N/A-58-48-45N/A6/30/2021N/A-45-39-36N/A3/31/2021N/A-40-35-31N/A12/31/2020N/A-33-27-25N/A9/30/2020N/A-29-22-20N/A6/30/2020N/A-86-28-26N/A3/31/2020N/A-76-20-19N/A12/31/2019N/A-69-16-15N/A9/30/2019N/A-66-21-21N/A6/30/2019N/A-22-29-29N/A3/31/201925-19-19-19N/A12/31/201825-32-32-32N/A9/30/201825-43-33-33N/A6/30/201825-40-30-30N/A3/31/2018N/A-56-49-49N/A12/31/2017N/A-50-45-45N/A9/30/2017N/A-45-43-42N/A6/30/2017N/A-41N/A-38N/A3/31/2017N/A-39N/A-36N/A12/31/2016N/A-37N/A-30N/A9/30/2016N/A-31N/A-25N/A6/30/2016N/A-28N/A-22N/A3/31/2016N/A-22N/A-20N/A12/31/2015N/A-22N/A-20N/A9/30/2015N/A-24N/A-23N/A6/30/2015N/A-26N/A-23N/A3/31/2015N/A-26N/A-20N/A12/31/2014N/A-24N/A-17N/A9/30/2014N/A-21N/A-15N/A6/30/2014N/A-19N/A-12N/A3/31/2014N/A-16N/A-11N/A12/31/2013N/A-15N/A-8N/A9/30/2013N/A-8N/A-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NLTXの予測収益成長が 貯蓄率 ( 2.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NLTXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NLTXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NLTXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NLTXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NLTXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/20 15:54終値2023/12/18 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neoleukin Therapeutics, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Michael UlzBairdGregory HarrisonBofA Global ResearchCorey DavisCanaccord Genuity11 その他のアナリストを表示
Price Target Changed • Sep 12Price target decreased to US$10.50Down from US$13.14, the current price target is an average from 6 analysts. New target price is 881% above last closing price of US$1.07. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • Aug 12Price target decreased to US$11.71Down from US$13.14, the current price target is an average from 6 analysts. New target price is 893% above last closing price of US$1.18. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • Jul 06Price target decreased to US$13.14Down from US$15.00, the current price target is an average from 5 analysts. New target price is 1,201% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • May 30Price target decreased to US$15.00Down from US$18.29, the current price target is an average from 6 analysts. New target price is 1,400% above last closing price of US$1.00. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • Apr 27Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 1,363% above last closing price of US$1.25. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • Mar 22Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 847% above last closing price of US$1.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.
お知らせ • Jan 16Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNeoleukin Therapeutics, Inc. announced the appointment of Julie Jordan, M.D., as Chief Medical Officer. Dr. Jordan brings to Neurogene over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. She most recently served as Chief Medical Officer of Homology Medicines, a clinical-stage company advancing gene therapies for the treatment of rare diseases. In her prior role as Chief Medical Officer of Homology Medicines, Dr. Jordan was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company’s pipeline of gene therapy and gene editing candidates for rare diseases. Prior to assuming her role as Chief Medical Officer, Dr. Jordan served as the company’s Senior Vice President, Head of Clinical Development and Operations. During her tenure, she successfully drove development and navigated regulatory challenges for multiple first-in-class genetic medicines, built and led a team of functional experts across multiple disciplines, and played a key role in strengthening relationships with patient advocacy groups and key opinion leaders. Before joining Homology Medicines, she held global leadership roles of increasing responsibility for central nervous system, neuropsychiatry, and other programs at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Before joining industry, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School.
お知らせ • Dec 20+ 1 more updateNeurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction.Neurogene Inc. entered into a term sheet to acquire Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders in a reverse merger transaction on June 2, 2023. Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $180 million in a reverse merger transaction on July 17, 2023. Subject to the terms of the merger agreement, each outstanding share of Neurogene capital stock will be converted solely into the right to receive a number of shares of Neoleukin common stock, equal to the exchange ratio, estimated to be approximately 1.7374 shares of Neoleukin common stock for each share of Neurogene’s common stock. Post merger Neoleukin stockholders are expected to own approximately 16% of the combined company and pre-merger Neurogene stockholders (including those purchasing Neurogene shares in the concurrent private financing) are expected to own approximately 84% of the combined company. Upon completion of the merger the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”. Under specified circumstances, Neoleukin may be required to pay Neurogene a termination fee of $3.04 million and Neurogene may be required to pay Neoleukin a termination fee of $12 million. The combined company will be led by Rachel McMinn, Founder and Chief Executive Officer of Neurogene, and other members of the Neurogene management team. The combined company’s Board of Directors will be comprised of five board members selected by Neurogene and two members selected by Neoleukin.The transaction is subject to approval by Neurogene and Neoleukin stockholders, the effectiveness of a registration statement, Nasdaq’s approval of the listing of the shares of Neoleukin common stock to be issued in connection with the merger, Neurogene’s receipt (or receipt simultaneous with the Closing of the merger) of cash proceeds from its private placement of not less than $75 million, Neoleukin net cash, as finally determined in accordance with the Merger Agreement, equaling an amount not less than $60 million and the satisfaction of customary closing conditions. The transaction has been unanimously approved by the Board of Directors of both Neurogene and Neoleukin. Neoleukin’s board of directors unanimously recommends that Neoleukin stockholders vote for the merger. The merger is expected to close in the fourth quarter of 2023. TD Cowen is serving as exclusive financial advisor to Neurogene. TD Cowen and Stifel are serving as placement agents on Neurogene’s planned concurrent private financing. Ryan A. Murr and Branden C. Berns of Gibson Dunn & Crutcher LLP are serving as legal counsel and legal due diligence provider to Neurogene and Cooley LLP is serving as legal counsel to the placement agents. Leerink Partners LLC acted as the exclusive financial advisor and fairness opinion provider to Neoleukin Board. David K. Michaels and Jeremy R. Delman of Fenwick & West LLP are serving as legal counsel and legal due diligence provider to Neoleukin. Equiniti Trust Company, LLC acted as transfer agent for Neoleukin and American Stock Transfer & Trust Company, LLC acted as transfer agent for Neurogene. Morrow Sodali LLC acted as proxy solicitor to Neoleukin for a fee of $20,000, plus reimbursement of out-of-pocket expenses. In connection with Leerink Partners’ services as financial advisor to Neoleukin, Neoleukin has agreed to pay Leerink Partners an aggregate fee of $2.5 million, $500,000 of which became payable upon the rendering of its opinion and the remainder of which is payable contingent upon consummation of the merger.Neurogene Inc. (NasdaqCM:NGNE) completed the acquisition of Neoleukin Therapeutics, Inc. (NasdaqCM:NLTX) from a group of shareholders for approximately $120 million in a reverse merger transaction on December 18, 2023. As a result of and upon the effective time of the Merger (as defined herein), among other things, (a) each then-issued and outstanding share of Class A Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class A Common Stock ”) converted automatically into 0.0756 shares of common stock, par value $0.000001 per share, of Neoleukin (the “Company Common Stock” and prior to the effective time of the Merger, the “Neoleukin Common Stock”), (b) each then-issued and outstanding share of Class B Common Stock, par value $0.0001 per share, of Neurogene (“Neurogene Class B Common Stock” and, together with Neurogene Class A Common Stock, “Neurogene Common Stock”), converted automatically into 0.0756 shares of Company Common Stock, (c) each then-issued and outstanding share of Series A-1 Preferred Stock, par value $0.0001 per share, of Neurogene (“ Neurogene Series A-1 Preferred Stock ”) converted automatically into 0.0756 shares of Company Common Stock, (d) each then-issued and outstanding share of Series A-2 Preferred Stock, par value $0.0001 per share, of Neurogene (“Neurogene Series A-2 Preferred Stock”) converted automatically into 0.0756 shares of Company Common Stock, (e) each then-issued and outstanding share of Series B Preferred Stock, par value $0.0001 per share (“Neurogene Series B Preferred Stock” and together with the Neurogene Common Stock, the Neurogene Series A-1 Preferred Stock and the Neurogene Series A-2 Preferred Stock, the “Neurogene Capital Stock”) converted automatically into 0.0756 shares of Company Common Stock, and (f) each then-issued and outstanding pre-funded warrant of Neurogene, each representing a right to acquire one share of Neurogene Common Stock for $1.559999 per pre-funded warrant (each, a “Neurogene Pre-Funded Warrant”), converted automatically, on a one-for-one basis, into a pre-funded warrant of the Company (each, a “ Company Pre-Funded Warrant”) that represents a right to acquire 0.0756 shares of Company Common Stock at an exercise price of $0.000001 per share. In connection with the completion of the Merger, Neoleukin changed its name from “Neoleukin Therapeutics, Inc.” to “Neurogene Inc.” (the “Company Name Change”). As of December 19, 2023, Neurogene shares are expected to begin trading on the NASDAQ Global Market under the ticker “NGNE” beginning today at the market open. The Board has determined that Robert Baffi, Cory Freedland, Sarah Noonberg, Rohan Palekar and Robert Keith Woods (“ Keith Woods ”), each of whom is a current member of the Board, qualify as “independent directors” as defined by the Nasdaq Listing Rules. The Neoleukin board of directors previously determined that former directors Martin Babler, M. Cantey Boyd, Erin Lavelle, Todd Simpson and Rusty Williams were “independent” under the Nasdaq Listing Rules. Immediately after the effective time the Merger on December 18, 2023, the Board appointed Rachel McMinn as the Company’s Chief Executive Officer and Christine Mikail as the Company’s President and Chief Financial Officer, each to serve at the discretion of the Board. Immediately after the effective time the Merger on December 18, 2023, the Board appointed the following four individuals to the Board: Rachel McMinn, Robert Baffi, Cory Freedland and Keith Woods. Rachel McMinn was also appointed as Chair of the Board. Concurrent with the closing of the merger, Neurogene closed an oversubscribed $95 million private financing, led by new and existing healthcare-dedicated specialist and mutual fund institutional investors, including participation from Great Point Partners, EcoR1 Capital, Redmile Group, Samsara BioCapital, Janus Henderson Investors, funds and accounts managed by Blackrock, Casdin Capital, Avidity Partners, Arrowmark Partners, Cormorant Asset Management, Alexandria Venture Investments, and a healthcare investment fund. Neurogene’s cash, cash equivalents, and investments of approximately $200 million, before payment of final transaction-related expenses, are expected to fund operations and multiple potentially value-creating milestones into the second half of 2026. Neoleukin convened and adjourned the Special Meeting on December 13, 2023. At the Special Meeting, Neoleukin’s stockholders approved, among other matters, amendments to the amended and restated certificate of incorporation of Neoleukin to (i) increase the number of authorized shares of Company Common Stock from 20,000,000 shares (after giving effect to the 1-for-5 reverse stock split that was effected on September 25, 2023) to 500,000,000 (the “Authorized Share Increase”) and (ii) effect the Reverse Stock Split. Following the Special Meeting, the Neoleukin board of directors approved the Reverse Stock Split at a ratio of 1:4.
お知らせ • Sep 23Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price RequirementNeoleukin Therapeutics, Inc. announced that its board of directors (‘Board’) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin’s common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin’s existing trading symbol ‘NLTX’ with a new CUSIP number 64049K203. The reverse stock split is part of Neoleukin’s plan to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share. The reverse stock split was approved by Neoleukin’s stockholders at the Company’s 2023 Annual Meeting of Stockholders held on June 8, 2023, to be effected in the Board’s discretion within approved parameters.
New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.3% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Market cap is less than US$100m (US$29.5m market cap).
分析記事 • Jul 18Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
分析記事 • Mar 10Here's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 19We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Board Change • Nov 16High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 3 experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 01Neoleukin Therapeutics Receives Notice from the Nasdaq Stock Market LLC for Minimum Bid Price RequirementOn October 26, 2022, Neoleukin Therapeutics, Inc. (the ‘Company’) received notice (the ‘Notice’) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (‘Nasdaq’) that, because the closing bid price for the Company's common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company's common stock on the Nasdaq Global Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until April 24, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to April 24, 2023. If the Company does not regain compliance by April 24, 2023, the Company may be eligible for an additional 180 calendar day grace period if it applies to transfer the listing of its common stock to the Nasdaq Capital Market. To qualify, the Company would be required to meet the continued listing requirement for the market value of its publicly held shares and all other initial listing standards for the Nasdaq Global Market, with the exception of the minimum bid price requirement, and provide written notice of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Nasdaq staff determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would have the right to appeal a determination to delist its common stock, and the common stock would remain listed on the Nasdaq Global Market until the completion of the appeal process. The Company is considering actions that it may take in response to this Notice in order to regain compliance with the continued listing requirements, but no decisions about a response have been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.
Price Target Changed • Sep 12Price target decreased to US$10.50Down from US$13.14, the current price target is an average from 6 analysts. New target price is 881% above last closing price of US$1.07. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.
Price Target Changed • Aug 12Price target decreased to US$11.71Down from US$13.14, the current price target is an average from 6 analysts. New target price is 893% above last closing price of US$1.18. Stock is down 83% over the past year. The company is forecast to post a net loss per share of US$1.20 next year compared to a net loss per share of US$1.10 last year.
お知らせ • Jul 28Neoleukin Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022Neoleukin Therapeutics, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 09, 2022
Price Target Changed • Jul 06Price target decreased to US$13.14Down from US$15.00, the current price target is an average from 5 analysts. New target price is 1,201% above last closing price of US$1.01. Stock is down 89% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.
お知らせ • Jun 26Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic IndexNeoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from Russell 2000 Dynamic Index
分析記事 • Jun 03Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • May 30Price target decreased to US$15.00Down from US$18.29, the current price target is an average from 6 analysts. New target price is 1,400% above last closing price of US$1.00. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.23 next year compared to a net loss per share of US$1.10 last year.
お知らせ • May 18Neoleukin Therapeutics, Inc. Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating Nl-201 in Combination with Keytruda® (Pembrolizumab)Neoleukin Therapeutics, Inc. announced treatment of the first patient in a combination arm evaluating the safety and efficacy of Neoleukin’s NL-201 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), as part of Neoleukin’s ongoing Phase 1 trial in patients with relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study, which is being conducted through a clinical collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
お知らせ • May 10Neoleukin Therapeutics, Inc. Provides NL-201 UpdateNeoleukin Therapeutics, Inc. provided NL-201 Update. Neoleukin is conducting a clinical trial of intravenous NL-201 in patients with advanced solid tumors. It is currently enrolling patients at sites in Australia, the United States, and Canada, evaluating two different schedules and multiple dose levels in order to determine a recommended Phase 2 dose and schedule. Neoleukin anticipates disclosing interim data during the second half of 2022. Based on encouraging preclinical activity, Neoleukin announced plans to initiate a separate clinical trial to evaluate NL-201 in patients with hematologic malignancies. The timing for enrolling patients in this trial will be determined based on data the company receive from the company's ongoing solid tumor Phase 1 trial relating to safety and optimal dosing schedules.
Price Target Changed • Apr 27Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 1,363% above last closing price of US$1.25. Stock is down 90% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. 1 highly experienced director. Independent Chairman Todd Simpson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 01Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022Neoleukin Therapeutics, Inc., Annual General Meeting, May 12, 2022, at 13:30 Pacific Standard Time. Agenda: To elect Jonathan G. Drachman and Sarah B. Noonberg as class ii directors of the company to hold office until the 2025 annual meeting of stockholders; to ratify the appointment of deloitte & touche llp as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2022; to approve, by a non-binding advisory vote, the compensation paid by the company to its named executive officers; and to conduct any other business properly brought before the meeting.
Price Target Changed • Mar 22Price target decreased to US$18.29Down from US$19.71, the current price target is an average from 6 analysts. New target price is 847% above last closing price of US$1.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$1.24 next year compared to a net loss per share of US$1.10 last year.
お知らせ • Mar 03Neoleukin Therapeutics Inc. Announces Executive ChangesNeoleukin Therapeutics Inc. announced the appointment of Rohan Palekar, Chief Executive Officer of 89bio, Inc, to Neoleukin's Board of Directors, and the departure of Lewis Rusty Williams, MD, PhD, from the board. Mr. Palekar has served as the CEO of 89bio since June 2018.
Price Target Changed • Mar 03Price target decreased to US$19.71Down from US$21.57, the current price target is an average from 6 analysts. New target price is 625% above last closing price of US$2.72. Stock is down 77% over the past year.
お知らせ • Feb 24Neoleukin Therapeutics, Inc. to Report Fiscal Year 2021 Results on Mar 01, 2022Neoleukin Therapeutics, Inc. announced that they will report fiscal year 2021 results After-Market on Mar 01, 2022
お知らせ • Feb 16+ 1 more updateNeoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.
お知らせ • Jan 12Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)Neoleukin Therapeutics, Inc. announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). The agreement will allow for the evaluation of safety and efficacy of Neoleukin’s NL-201, a de novo protein designed to mimic the therapeutic activity of natural cytokines IL-2 and IL-15, in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in an ongoing Phase 1 trial. Neoleukin will evaluate NL-201 plus pembrolizumab as part of the company’s ongoing Phase 1 trial in patients with advanced, relapsed or refractory solid tumors. Up to 132 patients will be enrolled in the combination arm of the study. The trial is assessing safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity.
お知らせ • Dec 12Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies At American Society of Hematology Annual MeetingNeoleukin Therapeutics, Inc. announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually and in person December 11-14, 2021. Additionally, a published abstract in Blood reports on NL-201 antitumor activity in preclinical studies of non-Hodgkin lymphoma. NL-201 is a de novo agonist of the IL-2 and IL-15 receptors, designed to expand cancer-fighting CD8 T cells and natural killer (NK) cells without a bias toward cells expressing the IL-2 receptor alpha subunit (CD25). NL-201 is currently in a Phase 1 clinical trial for patients with solid tumors.
Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 29General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 28General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after less than a year in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 27General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 26General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 25General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Nov 24General Counsel & Secretary Holly Vance has left the companyOn the 17th of November, Holly Vance's tenure as General Counsel & Secretary ended after 1.1 years in the role. We don't have any record of a personal shareholding under Holly's name. Holly is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.67 years, which is considered inexperienced in the Simply Wall St Risk Model.